Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is associated with a poor prognosis. Outcomes are particularly poor following immunochemotherapy failure or relapse within 12 months of induction. We conducted a Phase I/II trial of lenalidomide plus RICE (rituximab, ifosfamide, carboplatin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Tatyana, Mato, Anthony R, Chow, Kar F, Protomastro, Ewelina A, Yannotti, Kara M L, Bhattacharyya, Pritish, Yang, Xiao, Donato, Michele L, Rowley, Scott D, Carini, Carolanne, Valentinetti, Marisa, Smith, Judith, Gadaleta, Gabriella, Bejot, Coleen, Stives, Susan, Timberg, Mary, Kdiry, Sabrina, Pecora, Andrew L, Beaven, Anne W, Goy, Andre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283736/
https://www.ncbi.nlm.nih.gov/pubmed/24661044
http://dx.doi.org/10.1111/bjh.12846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283736/
https://www.ncbi.nlm.nih.gov/pubmed/24661044
http://dx.doi.org/10.1111/bjh.12846

Ejemplares similares